What is Zentek?
Zentek operates as an intellectual property development and commercialization firm, concentrating on next-generation healthcare solutions. Its primary focus is on the commercialization of ZenGUARD, a patent-pending antimicrobial coating that has demonstrated 99% efficacy against various pathogens, including SARS-CoV-2. The company is also leveraging its expertise to develop related compounds for infectious disease treatment and has secured exclusive global commercialization rights for a novel aptamer-based rapid pathogen detection technology. This dual approach positions Zentek at the forefront of preventative and diagnostic healthcare innovation.
How much funding has Zentek raised?
Zentek has raised a total of $1.8M across 1 funding round:
Private Equity
$1.8M
Private Equity (2026): $1.8M, investors not publicly disclosed
What's next for Zentek?
The substantial enterprise-level capital infusion and recent strategic investment provide Zentek with the resources necessary to accelerate the commercialization of ZenGUARD and its pathogen detection technology. The company is poised to expand its market reach and further develop its pipeline of healthcare solutions. Future growth is expected to be driven by strategic partnerships and the successful deployment of its patented technologies in both the treatment and detection of infectious diseases, marking a significant step in its evolution from an IP developer to a commercial-stage healthcare entity.
See full Zentek company page
